healthy volunteers F11.2 F12.2 F17.2
Conditions
Interventions
Group 1: Patients diagnosed with substance use disorders
25 patients diagnosed with opiate dependence, cannabis dependence and nicotine dependence respectively.
The examinations include:
• urin screening for ampethamines, benzodiazepines, cannabis, cocain
Sponsors
Zentralinstitut für Seelische Gesundheit, Klinik für Abhängiges Verhalten und Suchtmedizin
Eligibility
Sex/Gender
All
Age
25 Years to 50 Years
Inclusion criteria
Inclusion criteria: • age: between 25 and 50 years • Fully Informed Consent • Ability to undergo fMRI scanning • Written Informed Consent • In the clinical groups: diagnosed opiate addiction and opiate substitution treatment or diagnosed cannabis addiction or diagnosed nicotine addiction
Exclusion criteria
Exclusion criteria: • No Written Informed Consent • female participants: pregnancy (positive pregnancy test) or currently breastfeeding (anamnestic data) • Psychiotic disorders or other severe or difficult to manage psychiatric illnesses • Severe neurological or internal comorbidities • Psychotropic medication other than antidepressants from the category if SSRIs or Mirtazapin or Pipamperon • Severe drug consumption in addition to the index drug or acute intoxication • fMRI contraindications
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| • Measuring the excitatory/ inhibitory balance and resting state activity in the insula and the medial prefrontal cortex using multimodal magnetic resonance spectroscopy (fMRI, MRS, DTI). • Measuring executive functioning performance usnig neuropsychological tests | — |
Secondary
| Measure | Time frame |
|---|---|
| • Examination of biological markers for alcohol and drug abuse, epigenetic markers, inflammatory markers (IL-1, IL-4, IL-6, IL-8, IL-10, IL-12, TNF-alpha, INF-gamma, MCP-1) and microbiota. | — |
Countries
Germany
Contacts
Public ContactWolfgang Sommer
Zentralinstitut für Seelische Gesundheit, Klinik für Abhängiges Verhalten und Suchtmedizin
Outcome results
None listed